OS Therapies' (OSTX) "Buy" Rating Reaffirmed at D. Boral Capital

OS Therapies (NYSE:OSTX - Get Free Report)'s stock had its "buy" rating restated by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Lake Street Capital initiated coverage on OS Therapies in a research report on Wednesday, April 2nd. They set a "buy" rating and a $19.00 target price on the stock. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $18.00.

OS Therapies Stock Performance

Shares of OSTX stock opened at $1.84 on Monday. The firm's 50-day simple moving average is $1.76 and its two-hundred day simple moving average is $2.23. OS Therapies has a 52 week low of $1.12 and a 52 week high of $7.00. The firm has a market cap of $51.70 million and a price-to-earnings ratio of -2.14.

Insider Buying and Selling

In other news, major shareholder Shalom Auerbach sold 82,000 shares of the stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $2.00, for a total transaction of $164,000.00. Following the transaction, the insider now directly owns 2,664,199 shares in the company, valued at approximately $5,328,398. This represents a 2.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC increased its holdings in OS Therapies Inc (NYSE:OSTX - Free Report) by 172.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 300,000 shares of the company's stock after acquiring an additional 189,956 shares during the quarter. CM Management LLC owned about 1.38% of OS Therapies worth $462,000 as of its most recent filing with the Securities & Exchange Commission.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.